Revvity, Inc. · NYSE:RVTY
Revvity — Q1 2023 Earnings Presentation
9 slides from Revvity's earnings presentation, May 11, 2023
Slide 1: First Quarter 2023 Earnings
First Quarter 2023 Earnings May 11, 2023
Slide 2: Safe Harbor
Safe Harbor This presentation contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial
Slide 3: Key Takeaways
Key Takeaways Portfolio Transformation Launch Of Revvity 1Q Results Successfully completed divestiture of Analytical Global launch of the 1Q Non-COVID organic and Enterprise Solutions company as Revvity, Inc. growth and adjusted EPS business to New Mountain Stock ticker to change to at the upper-end
Slide 4: Q1'23 Revenue Highlights
Q123 Revenue Highlights Segments Geographic Product Mix Diagnostics Life Sciences AMERICAS APAC EU RECURRING NON-RECURRING +DD +DD +LSD $0.7 B +HSD +LSD $0.7 B $0.7 B +MSD +MSD 4 Revenue performance provided on a non-COVID organic basis Reconciliations to the most directly comparable GAAP measure fo
Slide 5: 1Q23 Financial Results
1Q23 Financial Results ADJUSTED REVENUE ADJUSTED OP MARGIN ADJUSTED EPS NON-GAAP FREE CASH FLOW $675M 28.0% $1.01 $51M -30% y/y -1,280bps y/y -56% y/y -63% y/y Includes $80M of AES & Organic: Adj. Gross Margin: Adj. Tax Rate: pension related outflows -27% | M&A: 0% | FX: -3% 62.4% | -510bps y/y 21.5
Slide 6: Life Sciences
Life Sciences Product REVENUE AJUSTED OP MARGINS REAGENTS INSTRUMENTS SOFTWARE -MSD +9% Organic Growth 39.4% Reported: 7% | M&A: 0% | FX: -2% +340bps y/y $328 M +DD • +MSD growth from Pharma/Biotech, +DD growth from 1Q23 revenue Academic/Gov’t +DD • Consistent +DD reagents organic growth + DD - HSD
Slide 7: Diagnostics
Diagnostics End Market REVENUE AJUSTED OP MARGINS IMMUNODX REPRODUCTIVE APPLIED HEALTH GENOMICS -44% Organic Growth 21.5% -LSD Reported: -47% | M&A: 0% | FX: -3% -2,430 bps y/y Non-COVID Organic Growth: 3% +MSD $344 M 1Q23 revenue +LSD • +DD ImmunoDx ex. China non-COVID organic growth • +DD Non-COVI
Slide 8: 2023 Financial Guidance
2023 Financial Guidance ADJ. REVENUE $2.90B - 2.94B -11% to –13% reported Organic: -11% to -13% Non-COVID Organic: +7% to +9% COVID: $3 million (vs. $617M in 2022) ADJUSTED OP. MARGIN 30% ADJUSTED EPS $4.85 - $5.05 Adj. Net interest expense, other: ~80M Adjusted tax rate: 21% Average diluted share c
Slide 9: Revvity.com
Revvity.com